NASDAQ$DVAX
Dynavax Technologies Corp · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2020.
Dynavax reported a net product revenue of $2.4 million for HEPLISAV-B in Q2 2020, which declined compared to $8.3 million in the same period in 2019 due to the COVID-19 pandemic. The company experienced a net loss of $51.6 million, which includes expense of $25.7 million due to an increase in the estimated fair value of outstanding warrants. Cash, cash equivalents and marketable securities totaled $200.7 million at June 30, 2020.
- HEPLISAV-B net product revenue was $2.4 million in the second quarter of 2020.
- Multiple new CpG 1018 collaborations were established to develop novel adjuvanted vaccine candidates across several indications, including COVID-19.
- Initial Phase 1 results from two COVID-19 adjuvanted vaccine collaborations are anticipated by September and October of 2020.
- The adult hepatitis B vaccine market experienced a significant decline early in the second quarter due to the pandemic.
Headline financials
Revenue & EPS history
Dynavax · Revenue · Quarterly
$2.67M
Revenue by segment
Dynavax · $2.41M total across 1 segment · Q2 2020
- HEPLISAV-B Net Product Revenue$2.41M-71.0%100.0%
Forward guidance
Dynavax is focused on the development and commercialization of novel vaccines, including HEPLISAV-B and CpG 1018-adjuvanted vaccines. The company anticipates several milestones in the coming quarters, including final immunogenicity data from the HEPLISAV-B hemodialysis study, completion of safety follow-up for HEPLISAV-B post-marketing studies, and preliminary results from Phase 1 COVID-19 studies.
Tailwinds
- Final immunogenicity data from the ongoing study of HEPLISAV-B in patients on hemodialysis anticipated in the fourth quarter with publication planned in the first quarter of 2021.
- Completion of safety follow-up for HEPLISAV-B post-marketing studies in the fourth quarter.
- Completion of Phase 1-enabling animal studies and toxicology for an improved pertussis vaccine with CpG 1018 is planned for the fourth quarter.
- Preliminary safety and immunogenicity results from Phase 1 COVID-19 studies with Clover Biopharmaceuticals and Medicago expected by September and October, respectively.
Headwinds
- The vaccine market and/or the adult hepatitis B market may not grow as expected.
- COVID-19 will continue to have a significant negative impact on the use of vaccines, including HEPLISAV-B, until the U.S. returns to more normal conditions.
- HEPLISAV-B may not provide the anticipated benefits and may not become the standard of care adult hepatitis B vaccine in the U.S.
- Our growth initiatives may not be successful.
- Risks related to the development and clinical testing of vaccines and whether use of CpG 1018 will prove to be beneficial in other vaccines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
-0.6%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+0.9%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+18.1%
Q1 2019
Best reaction
-29.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.5% | +2.4% | -1.0% | |
| Q2 2025 | -6.7% | -2.2% | -9.0% | |
| Q1 2025 | -11.0% | -9.6% | -6.1% | |
| Q4 2024 | +0.0% | +2.5% | +3.6% | |
| Q3 2024 | +5.9% | +9.6% | +4.5% | |
| Q2 2024 | +6.8% | +10.1% | +7.2% | |
| Q1 2024 | -6.4% | -6.2% | +2.6% | |
| Q4 2023 | +2.3% | +4.3% | -1.4% | |
| Q3 2023 | +0.9% | -5.5% | -2.8% | |
| Q2 2023 | +7.1% | +10.0% | +7.4% | |
| Q1 2023 | +4.8% | +7.0% | +9.0% | |
| Q4 2022 | -5.0% | -5.5% | -9.4% | |
| Q3 2022 | +11.6% | +10.3% | +12.6% | |
| Q2 2022 | +17.8% | +20.7% | -20.6% | |
| Q1 2022 | -4.3% | -12.0% | +29.7% | |
| Q4 2021 | -2.2% | -16.1% | -11.8% | |
| Q3 2021 | -22.8% | — | — | |
| Q2 2021 | +6.1% | — | — | |
| Q1 2021 | +9.7% | — | — | |
| Q4 2020 | -6.7% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | -13.5% | — | — | |
| Q1 2020 | -8.8% | — | — | |
| Q4 2019 | -29.1% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +5.2% | — | — | |
| Q1 2019 | +18.1% | — | — | |
| Q4 2018 | -7.8% | — | — | |
| Q3 2018 | +2.2% | — | — | |
| Q2 2018 | +5.8% | — | — | |
| Q1 2018 | -5.0% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +6.4% | — | — | |
| Q2 2017 | +12.7% | — | — | |
| Q1 2017 | +0.9% | — | — | |
| Q4 2016 | -2.5% | — | — | |
| Q3 2016 | +6.7% | — | — | |
| Q2 2016 | -2.3% | — | — | |
| Q1 2016 | +8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +10.8% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -9.2% | — | — | |
| Q1 2014 | -3.9% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | +4.5% | — | — | |
| Q2 2013 | +2.4% | — | — | |
| Q1 2013 | -5.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | -3.6% | — | — | |
| Q4 2011 | +3.1% | — | — | |
| Q3 2011 | -14.0% | — | — | |
| Q2 2011 | -14.6% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -8.1% | — | — | |
| Q1 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro